An interventional study of Vibrolung in Vibration and Respiratory Complications, sponsored by Astana Medical University. Recruiting at 1 site in Kazakhstan. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Astana Medical University · Not applicable, Interventional, and Basic science
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples.
In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Astana Medical University is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vibroacoustic physiotherapy
Device: Vibrolung
vibroacoustic physiotherapy
Device: Vibrolung
BARK VibroLUNG vibroacoustic device (No. RK-MT-7No.013611 dated October 7, 2014). The device is designed for the treatment and prevention of respiratory diseases. The device operates on the principle of exposure to a powerful vibroacoustic signal generated by special emitters. During the procedure, the emitters are pressed against the surface of the chest, and the procedure lasts an average of 5 minutes. The frequency of the signal constantly changes and has complex modulation, which ensures maximum effectiveness. Depending on the selected program, the signal can cause the effect of percussion, soft vibration, smooth alternation of acoustic signal and vibration, or combinations thereof.
Arterial blood gases
On day 1 of vibroacoustic therapy, arterial blood sampling will be performed to determine PaO2 (mmHg), PaC02 (mmHg), as well as for dynamics during transfer to the specialized department.
Time frame: Day 1
Chest X-ray
Chest X-ray at admission and after vibroacoustic therapy sessions at least twice in total, with technical capabilities(The X-ray image)
Time frame: Day 1
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astana Medical University